March 10 is National Women & Girls HIV/AIDS Awareness Day, and we've been seriously misled into underestimating the impact of ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...

Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.